Bertilimumab is under clinical development by Satellos Bioscience and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Bertilimumab’s likelihood of approval (LoA) and phase transition for Bullous Pemphigoid took place on 20 Nov 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Bertilimumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Bertilimumab overview

Bertilimumab (Ico-008, CAT-213) is under development for the treatment of vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis, allergic conjunctivitis and bullous pemphigoid and inflammatory diseases. The drug candidate is administered intravenously. The drug candidate is a human immunoglobulin monoclonal antibody targeting eotaxin-1. It was also under development for the treatment of primary sclerosing cholangitis (PSC), allergic rhinitis, Crohn's disease, psoriasis, ulcerative colitis, non-alcoholic steatohepatitis (NASH), acute asthma and atopic dermatitis.

Satellos Bioscience overview

Satellos Bioscience (Satellos) is medicine company, It offers various solution such as Muscular dystrophies, ageing muscle and muscle-wasting disorders. The company developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, Satellos has identified as a root cause of the progressive nature of this disease. The company operating under the brands MyoReGenX and Oral-Trans. The company also offers various partnership arrangements with other drug developers and universities. Sitellas is headquartered in Ontario, Canada.

Quick View Bertilimumab LOA Data

Report Segments
  • Innovator
Drug Name
  • Bertilimumab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Immunology
  • Ophthalmology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.